(Reuters) - The offer to take the company private follows the group's recent failure to clinch two major acquisitions, which would have made it one of the world's top three makers of generic medicines.
Actavis said in a statement that Novator, run by Bjorgolfur Bjorgolfsson, intended to offer 0.98 euros per share for all the A class shares in the firm, valuing the company at around 3.3 billion euros .
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment